cad-1005
·Code: CAD-1005, VLX-1005
cad-1005: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Cadrenal Therapeutics, Inc. (CVKD) | Phase 3 |
FDA Decisions
FDA_MeetingFDA provided guidance on protocol design, study population, dosing, background therapy, exposure, safety database, and primary endpoint for the Phase 3 pivotal trial.(CVKD)
Frequently asked questions
Who is developing cad-1005?
cad-1005 is being developed by Cadrenal Therapeutics, Inc..
What is cad-1005's latest FDA decision?
The most recent tracked FDA decision for cad-1005 is FDA_Meeting for FDA provided guidance on protocol design, study population, dosing, background therapy, exposure, safety database, and primary endpoint for the Phase 3 pivotal trial., dated April 30, 2026.
Get deeper analysis on cad-1005
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis